Antifibrotic therapies to control cardiac fibrosis

Area of Science:

• Cardiovascular Research
• Regenerative Medicine
• Biomaterials Science

Background:

• Cardiac fibrosis is a natural response to myocardial infarction, but its progression impairs heart function and can lead to heart failure.
• Myofibroblasts are key drivers of cardiac fibrosis, originating from various cell types and stimulated by growth factors like TGF-β.
• Current therapeutic strategies for cardiac fibrosis are limited, highlighting the need for effective interventions.

Purpose of the Study:

• To review current advancements in therapeutic approaches for inhibiting cardiac fibrosis progression.
• To explore strategies targeting myofibroblast formation and activity.
• To discuss the potential of localized delivery systems for antifibrotic therapies.

Main Methods:

• Review of existing literature on cardiac fibrosis and therapeutic interventions.
• Analysis of studies involving systemic and localized drug delivery.
• Examination of cell-based therapies and biomaterial applications.

Main Results:

• Myofibroblast inhibition strategies have shown efficacy in preventing cardiac fibrosis.
• Localized delivery of antifibrotic drugs and biomaterials offers promising therapeutic potential.
• Cell-based therapies, when combined with biomaterials, represent an emerging treatment avenue.

Conclusions:

• Inhibiting myofibroblast formation is crucial for preventing cardiac fibrosis progression post-myocardial infarction.
• Localized therapeutic delivery systems, including biomaterials and cell-based approaches, are key areas for future development.
• Further research is needed to establish efficient and safe therapeutic strategies to combat cardiac fibrosis and prevent heart failure.